Treatment-related adverse events of chimeric antigen receptor T-cell (CAR T) in clinical trials: a systematic review and meta-analysis. Cancers (Basel) (2021) 13(15):1–25. doi: 10.3390/cancers13153912 2. Yi‑Jou C, Michael C, Tian‑Lu C, et al. A non-genetic engineering platform...
Clinical Research Services: Experts. Early Phase. We offer in-house solutions to support your early phase clinical trial. Discover our services today.
最近做的项目,特别是安全性的一块,都涉及了CRS的一些summary,借此机会学习一下这个免疫治疗领域的安全性的新对手。本文总结自《Harmonizing the Definition and Reporting of Cytokine Release Syndrome (CRS) in Immuno-Oncology Clinical Trials》白皮书。作为一名programmer,更关注事件及相关数据的收集/呈现/意义,对于临...
Thus far, the use of CRS and HIPEC in metastatic gastric, ovarian, pancreatic, and other gastrointestinal malignancies has spurred further development of a growing number of prospective clinical trials to study outcomes and survival benefit. This chapter summarizes some of the notable, completed ...
Our findings suggested that the higher the CRS at the interval cytoreduction, the better the subsequent PARPi response. CRS correlates with PARPi response, as the HRD test does in other clinical trials and it may be cons...
1. Lei W, Xie M, Jiang Q, Xu N, Li P, Liang A, et al. Treatment-related adverse events of chimeric antigen receptor T-cell (CAR T) in clinical trials: a systematic review and meta-analysis. Cancers (Basel) (2021) 13(15):1–25. doi: 10.3390/cancers13153912 ...
T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis. Cancers (Basel). 2021 Aug 3;13(15):3912. doi: 10.3390/cancers13153912. PMID: 34359816; PMCID: PMC8345443.
来源于:NCCN Clinical Practice Guidelines in Oncology 早期ICANS症状常表现为局部的神经系统受损,可采用抗癫痫预防措施。2级或以上ICANS可使用皮质激素或地塞米松,是ICANS治疗的主要手段,遵循最低治疗剂量、最短治疗时间、快速减量的原则。病情特别严重者可予甲泼尼龙每天1g的方案进行冲击治疗2~3天。
对于胃癌 (GC) 引起的腹膜转移 (PM) 患者,化疗是首选治疗方法。细胞减灭术 (CRS) 和腹腔热内化疗 (HIPEC) 仍在争论中。这项随机、对照、开放标签、多中心 III 期试验(EudraCT 2006-006088-22;ClinicalTrials.gov 标识符:NCT02158988)探讨了 CRS 后 HIPEC 对总生存期 (OS) 的影响。
In clinical trials of the Light Adjustable Lens (RxSight), investigators reported excellent results with this first-of-its-kind IOL, including reduction in treated astigmatism, excellent UCVA, and a sharp reduction in residual spherical error.1 ...